CARsgen Therapeutics' (HKG:2171) CT0596 obtained investigational new drug clearance from China's National Medical Products Administration, according to a Monday Hong Kong bourse filing.
Shares of the biopharmaceutical company were up nearly 3% in afternoon trading on Tuesday.
The drug is for the treatment of patients with relapsed/refractory multiple myeloma.